INVEGA TRINZA® Common Dosing and Administration Topics

Missed Dose

Management of Missed Dose - 4 to 9 Months Since Last Injection

Consistent with the INVEGA TRINZA® Prescribing Information:

  • If 4 months up to and including 9 months have elapsed since the last injection of INVEGA TRINZA®, do NOT administer the next dose of INVEGA TRINZA®. Instead, use the re-initiation regimen shown in the table below.

Re-initiation Regimen After Missing 4 Months to 9 Months of INVEGA TRINZA®

If the Last Dose of INVEGA TRINZA® was:

Administer INVEGA SUSTENNA®, two doses one week apart (into deltoid muscle)

Then administer INVEGA TRINZA® (into deltoida or gluteal muscle)

Day 1

Day 8

1 month after Day 8

273 mg

78 mg

78 mg

273 mg

410 mg

117 mg

117 mg

410 mg

546 mg

156 mg

156 mg

546 mg

819 mg

156 mg

156 mg

819 mg

a See Instructions for Use for deltoid injection needle selection based on body weight.

For illustrative displays of this dosing scenario, please click the links below.

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel